Skip to content

Clinical trials

Completed Phase 3 Leukemia, Myeloid, Acute trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Phase: Phase 3 Status: Completed Clear all

130 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20011
200211
20031
20047
20056
20067
20075
20089
20092
20108
20117
20123
20134
20147
20153
20163
20176
20187
20192
20202
20211
20221
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed130

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center6
European Organisation for Research and Treatment of Cancer - EORTC5
National Cancer Institute (NCI)5
St. Jude Children's Research Hospital5
University of Ulm5
AbbVie4
M.D. Anderson Cancer Center4
Acute Leukemia French Association3
Astellas Pharma Global Development, Inc.3
Astex Pharmaceuticals, Inc.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute130
Leukemia38
Myelodysplastic Syndromes35
Precursor Cell Lymphoblastic Leukemia-Lymphoma33
Lymphoma, Non-Hodgkin25
Hodgkin Disease23
Leukemia, Lymphocytic, Chronic, B-Cell21
Multiple Myeloma20
Congenital Abnormalities19
Lymphoma, Mantle-Cell19

Trials

Showing 1 to 25 of 130. Each trial links to its page on Pharma Observatory.

30 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.